Dataset Information


Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.

ABSTRACT: Nanocarriers delivering prodrugs are a way of improving in vivo effectiveness and efficiency. For therapeutic efficacy, the prodrug must hydrolyze to its parent drug after administration. Based on the fact that the hydrolysis is impeded by steric hindrance and improved by sufficient polarity, in this study, we proposed the PTX-S-S-VE, the conjugation of paclitaxel (PTX) to vitamin E (VE) through a disulfide bridge. This conjugate possessed the following advantages: first, it can be encapsulated in the VE/VE2-PEG2000/water nanoemulsions because of favorable hydrophobic interactions; second, the nanoemulsions had a long blood circulation time; finally, the concentrated glutathione in the tumor microenvironment could cleave the disulfide bond to weaken the steric hindrance and increase the polarity, promoting the hydrolysis to PTX and increasing the anticancer activity. It was demonstrated in vitro that the hydrolysis of PTX-S-S-VE was enhanced and the cytotoxicity was increased. In addition, PTX-S-S-VE had greater anticancer activity against the KB-3-1 cell line tumor xenograft and the tumor size was smaller after the 4(th) injection. The present result suggests a new way, use of reduction, to improve the in vivo anticancer activity of a prodrug for nanocarrier delivery by unshielding the ester bond and taking off the steric block.


PROVIDER: S-EPMC4499798 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4144753 | BioStudies
2015-01-01 | S-EPMC4729777 | BioStudies
2019-01-01 | S-EPMC6918103 | BioStudies
2009-01-01 | S-EPMC2868194 | BioStudies
2020-01-01 | S-EPMC7470106 | BioStudies
2016-01-01 | S-EPMC5541379 | BioStudies
1000-01-01 | S-EPMC6321537 | BioStudies
2017-01-01 | S-EPMC6418821 | BioStudies
2016-01-01 | S-EPMC5012958 | BioStudies
2016-01-01 | S-EPMC5206766 | BioStudies